COMMUNIQUÉS West-GlobeNewswire

Aleafia Announces Special Meeting of Shareholders

07/11/2018 - 13:00

TORONTO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. ( TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH ) (“ Aleafia “) or (the “ Company “) is announcing that it will hold a special meeting (the “ Meeting ”) of [...]

Emerald Health Therapeutics Fulfilling Supply Commitments with Provincial Adult-Use Cannabis Shipments

07/11/2018 - 13:00

Emerald delivers first shipments to British Columbia and Newfoundland and Labrador VICTORIA, British Columbia, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) has [...]

Clementia Reports Third Quarter 2018 Operating Results and Pipeline Updates

07/11/2018 - 12:30

Recent FDA Meeting Identifies Path Towards NDA Submission in the Second Half of 2019 Financing Raises $75 million to Support a Potential Commercial Launch MONTREAL, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Clementia [...]

Clementia présente ses résultats d’exploitation pour le troisième trimestre de 2018, ainsi qu’une mise à jour de son portefeuille de produits

07/11/2018 - 12:30

Une rencontre récente avec la FDA ouvre la voie à la soumission d’une NDA au second semestre de 2019 Une activité de financement rapporte 75 M$ pour la réalisation d’un lancement commercial potentiel MONTRÉAL, 07 nov. [...]

Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea

07/11/2018 - 12:00

FMX103 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints Conference Call and Webcast Today at 8:30 a.m. ET REHOVOT, Israel and BRIDGEWATER, N.J., Nov. [...]

A Q&A Session With RavenQuest CEO George Robinson

07/11/2018 - 12:00

VANCOUVER, British Columbia, Nov. 07, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT) We’re heading swiftly through the final quarter of 2018 and [...]

Momenta Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update

07/11/2018 - 12:00

CAMBRIDGE, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today reported its financial results for the third quarter ended September 30, 2018 and provided a corporate update. “We [...]

Achillion Reports Third Quarter 2018 Financial Results

07/11/2018 - 12:00

- Completed enrollment of Phase 2 clinical trial of ACH-4471 in PNH as monotherapy - - Interim data and strategic update planned for December 17, 2018 – - September 30, 2018 cash & securities position of $283 [...]

Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences

07/11/2018 - 12:00

WATERTOWN, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening [...]

Immunicum AB (publ) Interim Report July - September 2018

07/11/2018 - 08:01

Press Release 7 November 2018 Immunicum AB (publ) Interim Report July - September 2018 Positive preclinical results presented at ESMO Significant Events During the Third Quarter Immunicum announced protocol approval by [...]

Rule 2.9 Announcement

07/11/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 7 November 2018 [...]

Sensorion Announces Presentation of SENS-401 Poster at Society for Neuroscience 2018 Annual Meeting

07/11/2018 - 08:00

Preclinical data suggest efficacy of SENS-401 is not affected by concomitant administration of a corticosteroid Adds to evidence supporting use of SENS-401 in sudden sensorineural hearing loss (SSNHL) Phase II trial of [...]

Lundbeck realized 12% growth in revenue (local currencies) and 56% growth in EPS in 9M 2018. Guidance for FY2018 raised

07/11/2018 - 07:42

Valby, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Financial report for the period 1 January to 30 September 2018 Lundbeck realized 12% growth in revenue (local currencies) and 56% growth in EPS in 9M 2018. Guidance for FY2018 [...]

MDxHealth (R): SelectMDx improves prostate biopsy decision-making in urology practices

07/11/2018 - 07:35

NEWS RELEASE REGULATED INFORMATION Real-world study shows that SelectMDx helps urologists more confidently determine the need for an initial prostate biopsy IRVINE, CA, and HERSTAL, BELGIUM - 07.00 CEST, 7 November 2018 [...]

MDxHealth (R): SelectMDx améliore la prise de décision en matière de biopsie de la prostate dans les cabinets d'urologie

07/11/2018 - 07:35

COMMUNIQUÉ DE PRESSE INFORMATIONS RÉGLEMENTÉES Une enquête menée en situation réelle prouve que le test SelectMDx aide les urologues à mieux établir le besoin de procéder ou non à une biopsie de la prostate initiale [...]

ObsEva SA to Participate in November Investor Conferences

07/11/2018 - 07:30

Geneva, Switzerland and Boston, MA – November 7, 2018 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]

Esperite Group with The Cell Factory, expands its patent portfolio on extra-cellular vesicles biologic drugs in Canada.

07/11/2018 - 07:18

Amsterdam, the Netherlands - 7 November 2018 Esperite's (Euronext: ESP) biotech company The Cell Factory has obtained the patent for the use of extracellular vesicles (EVs) in the treatment of acute and chronic [...]

Bone Therapeutics Business Update for Third Quarter 2018

07/11/2018 - 07:00

Regulated information Positive efficacy and safety results in ALLOB Delayed Union Phase I/II trial, supporting next stage in clinical development Manufacturing process optimisation implemented for allogeneic platform [...]

Bone Therapeutics publie son rapport d’activité du troisième trimestre 2018

07/11/2018 - 07:00

Information réglementée Résultats positifs d’efficacité et de sécurité de l’étude de Phase I/II avec ALLOB dans les fractures avec retard de consolidation, encourageant la poursuite du développement clinique Mise en [...]